LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer

Oncogene

Volumn 35, Issue 21, 2016, Pages 2746-2755

  Xue, X ^a,b   Yang, Y A ^b   Zhang, A ^b   Fong, K W ^b   Kim, J ^b   Song, B ^b   Li, S ^b   Zhao, J C ^b   Yu, J ^b  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR; HOX ANTISENSE INTERGENIC RNA; LONG UNTRANSLATED RNA; TAMOXIFEN; UNCLASSIFIED DRUG; ANTIESTROGEN; HOTAIR LONG UNTRANSLATED RNA, HUMAN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DNA TEMPLATE; ENHANCER REGION; GENE CONTROL; GENE ONTOLOGY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROMOTER REGION; RNA PROBE; TRANSCRIPTION INITIATION SITE; UPREGULATION; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; METABOLISM; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; RECEPTORS, ESTROGEN; RNA, LONG NONCODING; SIGNAL TRANSDUCTION; TAMOXIFEN; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84941670564     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.340     Document Type: Article

References (36)

1. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet 2009; 10: 155-159.
2. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell 2009; 136: 629-641.
3. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell 2011; 43: 904-914.
4. Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev 2009; 23: 1494-1504.
5. Yoon JH, Abdelmohsen K, Kim J, Yang X, Martindale JL, Tominaga-Yamanaka K et al. Scaffold function of long non-coding RNA HOTAIR in protein ubiquitination. Nat Commun 2013; 4: 2939.
6. Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y et al. The landscape of long noncoding RNAs in the human transcriptome. Nat Genet 2015; 47: 199-208.
7. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010; 464: 1071-1076.
8. Gupta S, Iljin K, Sara H, Mpindi JP, Mirtti T, Vainio P et al. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 2010; 70: 6735-6745.
9. Chisholm KM, Wan Y, Li R, Montgomery KD, Chang HY, West RB. Detection of long non-coding RNA in archival tissue: correlation with polycomb protein expression in primary and metastatic breast carcinoma. PLoS One 2012; 7: e47998.
10. Sorensen KP, Thomassen M, Tan Q, Bak M, Cold S, Burton M et al. Long noncoding RNA HOTAIR is an independent prognostic marker of metastasis in estrogen receptor-positive primary breast cancer. Breast Cancer Res Treat 2013; 142: 529-536.
11. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004; 11: 643-658.
12. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9: 631-643.
13. Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Musgrove EA, Sutherland RL. Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer 2003; 10: 179-186.
14. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 2000; 103: 843-852.
15. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998; 95: 927-937.
16. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 2012; 481: 389-393.
17. Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 2006; 66: 11954-11966.
18. Joseph R, Orlov YL, Huss M, Sun W, Kong SL, Ukil L et al. Integrative model of genomic factors for determining binding site selection by estrogen receptor-alpha. Mol Syst Biol 2010; 6: 456.
19. Kaneko S, Li G, Son J, Xu CF, Margueron R, Neubert TA et al. Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA. Genes Dev 2010; 24: 2615-2620.
20. Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 2010; 329: 689-693.
21. Mourtada-Maarabouni M, Pickard MR, Hedge VL, Farzaneh F, Williams GT. GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene 2009; 28: 195-208.
22. Zhou Y, Zhong Y, Wang Y, Zhang X, Batista DL, Gejman R et al. Activation of p53 by MEG3 non-coding RNA. J Biol Chem 2007; 282: 24731-24742.
23. Chen D, Sun Y, Wei Y, Zhang P, Rezaeian AH, Teruya-Feldstein J et al. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med 2012; 18: 1511-1517.
24. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59: 5975-5979.
25. Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol 2011; 29: 742-749.
26. Prensner JR, Iyer MK, Sahu A, Asangani IA, Cao Q, Patel L et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet 2013; 45: 1392-1398.
27. Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology. Cancer Discovery 2011; 1: 391-407.
28. Lee GL, Dobi A, Srivastava S. Prostate cancer: diagnostic performance of the PCA3 urine test. Nat Rev Urol 2011; 8: 123-124.
29. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010; 464: 1067-1070.
30. Clarke R, Leonessa F, Welch JN, Skaar TC. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 2001; 53: 25-71.
31. Wu L, Runkle C, Jin HJ, Yu J, Li J, Yang X et al. CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor. Oncogene 2014; 33: 504-513.
32. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi WX et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015; 43: e47.
33. Huang, da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
34. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
35. Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010; 17: 443-454.
36. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler Transform. Bioinformatics 2009; 25: 1754-1760.